Answers are grounded in this paper and cite their sources.
Our results demonstrate that high nuclear expression of RBM3 in prostate cancer is associated with a prolonged time to disease progression and, thus, a potential biomarker of favourable prognosis. The value of RBM3 for prognostication, treatment stratification and follow-up of prostate cancer patients should be further validated in larger studies.
No takes yet. Share an insight, caveat, or question.
Jonsson et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: